The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
Open accessAbstract
BACKGROUND: Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies. METHODS: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, randomised controlled trial that enrolled adults with newly diagnosed active Crohn's disease (Harvey-Bradshaw Index ≥7, either elevated C-reactive protein or faecal calprotectin or both, and endoscopic evidence of active inflammation). Potential participants had blood drawn to be tested for a prognostic biomarker derived from T-cell transcriptional signatures (PredictSURE-IBD assay). Following testing, patients were randomly assigned, via a secure online platform, to top-down or accelerated step-up treatment stratified by biomarker subgroup (IBDhi or IBDlo), endoscopic inflammation (mild, moderate, or severe), and extent (colonic or other). Blinding to biomarker status was maintained throughout the trial. The primary endpoint was sustained steroid-free and surgery-free remission to week 48. Remission was defined by a composite of symptoms and inflammatory markers at all visits. Flare required active symptoms (HBI ≥5) plus raised inflammatory markers (CRP >upper limit of normal or faecal calprotectin ≥200 μg/g, or both), while remission was the converse-ie, quiescent symptoms (HBI <5) or resolved inflammatory markers (both CRP ≤ the upper limit of normal and calprotectin <200 μg/g) or both. Analyses were done in the full analysis (intention-to-treat) population. The trial has completed and is registered (ISRCTN11808228). FINDINGS: Between Dec 29, 2017, and Jan 5, 2022, 386 patients (mean age 33·6 years [SD 13·2]; 179 [46%] female, 207 [54%] male) were randomised: 193 to the top-down group and 193 to the accelerated step-up group. Median time from diagnosis to trial enrolment was 12 days (range 0-191). Primary outcome data were available for 379 participants (189 in the top-down group; 190 in the accelerated step-up group). There was no biomarker-treatment interaction effect (absolute difference 1 percentage points, 95% CI -15 to 15; p=0·944). Sustained steroid-free and surgery-free remission was significantly more frequent in the top-down group than in the accelerated step-up group (149 [79%] of 189 patients vs 29 [15%] of 190 patients, absolute difference 64 percentage points, 95% CI 57 to 72; p<0·0001). There were fewer adverse events (including disease flares) and serious adverse events in the top-down group than in the accelerated step-up group (adverse events: 168 vs 315; serious adverse events: 15 vs 42), with fewer complications requiring abdominal surgery (one vs ten) and no difference in serious infections (three vs eight). INTERPRETATION: Top-down treatment with combination infliximab plus immunomodulator achieved substantially better outcomes at 1 year than accelerated step-up treatment. The biomarker did not show clinical utility. Top-down treatment should be considered standard of care for patients with newly diagnosed active Crohn's disease. FUNDING: Wellcome and PredictImmune Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Self-citationECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Self-citationLong-Term Evolution of Disease Behavior of Crohn's Disease
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., & Gendre, J.-P. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00002 · Cited by 1,346
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Self-citationColombel, J.-F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vaňásek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hébuterne, X., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32641-7 · Cited by 921
Self-citationT-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A., & Smith, K. G. C. (2015) · Nature · doi:10.1038/nature14468 · Cited by 685 · cited 1×
“27,28 Care had been taken during biomarker develop ment to prevent over-fitting and independently validate associations with clinical outcome in two real-world cohorts.”
ResultSelf-citationKhanna, R., Bressler, B., Levesque, B. G., Zou, G., Stitt, L. W., Greenberg, G. R., Panaccione, R., Bitton, A., Paré, P., Vermeire, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00068-9 · Cited by 460
Self-citationFeuerstein, J. D., Ho, E. Y., Shmidt, E., Singh, H., Falck-Ytter, Y., Sultan, S., Terdiman, J. P., Sultan, S., Cohen, B. L., Chachu, K., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.022 · Cited by 407
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Self-citationShah, S. C., Colombel, J. ‐., Sands, B. E., & Narula, N. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13475 · Cited by 357
Cited by
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Self-citation
Metadata
- Authors
- Noor, N. M., Lee, J. C., Bond, S., Dowling, F., Brezina, B., Patel, K. V., Ahmad, T., Banim, P. J., Berrill, J. W., Cooney, R., De La Revilla Negro, J., de Silva, S., Din, S., Durai, D., Gordon, J. N., Irving, P. M., Johnson, M., Kent, A. J., Kok, K. B., Moran, G. W., Mowat, C., Patel, P., Probert, C. S., Raine, T., Saich, R., Seward, A., Sharpstone, D., Smith, M. A., Subramanian, S., Upponi, S. S., Wiles, A., Williams, H. R. T., van den Brink, G. R., Vermeire, S., Jairath, V., D'Haens, G. R., McKinney, E. F., Lyons, P. A., Lindsay, J. O., Kennedy, N. A., Smith, K. G. C., Parkes, M., Noor, N., Lee, J., Bond, S., Dowling, F., Brezina, B., Patel, K., Ahmad, T., Banim, P., Berrill, J., Cooney, R., De La Revilla Negro, J., de Silva, S., Din, S., Durai, D., Gordon, J., Irving, P., Johnson, M., Kent, A., Kok, K. B., Moran, G., Mowat, C., Patel, P., Probert, C., Raine, T., Saich, R., Seward, A., Sharpstone, D., Smith, M., Subramanian, S., Upponi, S., Wiles, A., Williams, H., van Den Brink, G., Vermeire, S., Jairath, V., D'Haens, G., McKinney, E., Lyons, P., Lindsay, J., Kennedy, N., Smith, K., Parkes, M., Allcock, C., Bhatti, S., Blackwell, J., Boulton-Jones, R., Brookes, M., Butcher, R., Butterworth, J., Champion, K., Chaudhary, R., Cole, A., Derikx, L., Dhar, A., Flowerdew, M., Goel, R., Hart, A., Hughes, R., Javaid, B., Knight, P., Lee, J., Lees, C., Levell, E., Li, A., Murray, C., O'Brien, L., Parkes, G., Pollok, R., Powles, S., Ramdas, A., Smith, P., Speight, R. A., Travis, S., Weaver, S., & Wesley, E.
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 9
- Issue
- 5
- Pages
- 415-427
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W4392059660
- Cited by
- 310
- References
- 25
- FWCI
- 74.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2468-1253(24)00034-7
- The paper
- Noor, N. M., Lee, J. C., Bond, S., Dowling, F., Brezina, B., Patel, K. V., Ahmad, T., Banim, P. J., Berrill, J. W., Cooney, R., De La Revilla Negro, J., de Silva, S., Din, S., Durai, D., Gordon, J. N., Irving, P. M., Johnson, M., Kent, A. J., Kok, K. B., . . . Wesley, E. (2024). A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00034-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.